Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod and HPV vaccine for CIN 2/3
NCT02864147Phase 2Completed
- Sponsor
- Yale University
- Start
- Jul 2016
- Primary completion
- May 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human papillomavirus 9-valent vaccine, imiquimod in cervical intraepithelial neoplasia (CIN), sponsored by Yale University. Started Jul 2016; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccineimiquimod
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT02864147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02864147.